Residual Cancer clinical trials at University of California Health

1 in progress, 0 open to eligible people

Showing trials for

  • Atezolizumab + Sacituzumab Govitecan to Prevent Recurrence in TNBC (ASPRIA)

    Sorry, in progress, not accepting new patients

    The purpose of this study is to determine if a combination of two drugs ipatasertib and atezolizumab works as a treatment for residual cancer in the breast or lymph nodes and have circulating tumor DNA in the blood. This research study involves the…

    at UCSF

Our lead scientists for Residual Cancer research studies include .

Last updated: